Tenax Therapeutics Inc
TENX
Get informed when a big investor buys or sells
+ FollowMarket Cap$45.62M
Close$
$2.49
44.6% upside
Current Fair Value
44.6% upsideUndervalued by 44.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $45.62 Million |
|---|---|
| Enterprise Value | $-72,352,727.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.34 |
| Beta | 0.92 |
| Outstanding Shares | 50,869,259 |
Return
| Return on Equity | -57.10% |
|---|---|
| Return on Assets | -53.31% |
| Return on Invested Capital | 4.12% |
Valuation & Multiples
| P/E Ratio | -1.15 |
|---|---|
| PEG | -1.8 |
| Price to Sales | - |
| Price to Book Ratio | 0.86 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -15.45 |
| Enterprise Value to Net Income | 1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 18, 2026
EPS Estimate
$-0.40
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
$-0.35
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 18.31% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.00%▼ 59.76% |
|---|---|
| Total Invested | $4,394▼ 100.00% |
| Investors Holding | 1▼ 128.00% |
ESG Score
No data
About Tenax Therapeutics Inc
CEO: John Kelley